A case with Gaucher disease unable to reach enzyme replacement therapy because of COVID-19 quarantine: The first case from Turkey

References (9)

1. Parvaneh N, Quartier P, Rostami P, et al. Inborn errors of metabolism underlying primary immunodeficiencies. J Clin Immunol 2014; 34:753-71
2. Leoni C, Giorgio V, Onesimo R, et al. The dark side of COVID-19: The need of integrated medicine for children with special care needs. Am J Med Genet A 2020; 182: 1988-9
3. Zimran A, Hollak CE, Abrahamov A, et al. Home treatment with intravenous enzyme replacement therapy for Gaucher disease: An international collaborative study of 33 patients. Blood 1993; 82: 1107-9
4. Caciotti A, Procopio E, Pochiero F, et al. SARS-CoV-2 infection in a patient with propionic acidemia. Orphanet J Rare Dis 2020; 15: 306
5. Zimran A, Szer J, Revel-Vilk S. Impact of Gaucher disease on COVID-19. Intern Med J 2020; 50: 894-5
6. Fierro L, Nesheiwat N, Narayanan P, et al. Gaucher disease and SARS-CoV-2 infection: Experience from 181 patients in New York. Mol Genet and Metab 2020; 132: 44-8
7. Mistry P, Balwani M, Babouth D, et al. Gaucher disease and SARSCoV-2 infection: Emerging management challenges. Mol Genet and Metab. 2020; 130(3): 164-169
8. Elmonem MA, Belanger-Quintana A, Bordugo A, et al. The impact of COVID-19 pandemic on the diagnosis and management of inborn errors of metabolism: A global perspective. Mol Genet Metab 2020; 131: 285-88
9. EURORDIS Rare Diseases Europe 2020. How has COVID-19 impacted people with rare diseases? Available from: https://download2.eurordis.org/rbv/covid19survey/covid_infographics_final. pdf 10. Campos MA, Azuara BE, Frutos LL, et al. Direct and indirect effects of the SARS-CoV-2 pandemic on Gaucher Disease patients in Spain: Time to reconsider home-based therapies? Blood Cells Mol Dis 2020; 85: 102478.